dengue%20(pediatric)
DENGUE (PEDIATRIC)
Dengue infection is caused by the dengue virus that belongs to the family Flaviviridae.
There are 4 serotypes (DENV-1, DENV-2, DENV-3, DENV-4). Each serotype provides specific lifetime protective immunity against reinfection of the same serotype, but only temporary (within 2-3 months of the primary infection) and partial protection against other serotypes.
It is transmitted to humans through the bites of infected Aedes mosquitoes. It is primarily transmitted by female Aedes aegypti, a tropical and subtropical species. Humans are the main host of the virus.
After 4-10 days of incubation period, illness begins immediately.
  1. Songco RS, Purugganan H, Carandang EH, et al. AdHoc Committee on Dengue Infections of the Philippine Pediatric Society. Guidelines for the diagnosis and treatment of dengue hemorrhagic fever/dengue shock syndrome. Quezon City, PH: Philippine Pediatric Society Inc; 1998
  2. Philippine Pediatric Society Inc. Handbook of infectious diseases. Quezon City, PH: Philippine Pediatric Society Inc; 2004
  3. Malaria & Vector Borne Diseases Control Unit Disease Control Directorate Directorate General of Health Services Ministry of Health & Family Welfare & WHO Bangladesh. National guidelines for clinical management of dengue syndrome. 1st ed. Bangladesh: Disease Control Directorate of Directorate General of Health Services, Ministry of Health & Family Welfare of Government of Peoples Republic of Bangladesh; 2000.
  4. Gunn VL, Nechyba C, eds. The Harriet Lane handbook: a manual for pediatric house officers. 16th ed. St. Louis, MO: MD Consult LLC; 2002.
  5. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  6. Technical Working Group on the 2010 PPS Interim Guidelines on Fluid Management of DF/DHF. 2010 Interim guidelines on fluid management of dengue fever and dengue hemorrhagic fever. http://www.pps.org.ph/. Feb 2011. Accessed 29 Nov 2011.
  7. Ministry of Health Singapore. Clinical Guidelines on dengue fever (DF)/dengue hemorrhagic fever (DHF). Ministry of Health Singapore. http://www.moh.gov.sg/. 2002.
  8. World Health Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. World Health Organization Web Site. http://www.who.int/. 1997.
  9. World Health Organization Regional Office for Southeast Asia. Guidelines for treatment of dengue fever/dengue hemorrhagic fever in small hospitals. WHO. http://www.searo.who.int/. 1999.
  10. World Health Organization (WHO) and Special Programme for Research and Training in Tropical Diseases (TDR). Dengue: guidelines for diagnosis, treatment, prevention and control - new edition. WHO Web Site. http://whqlibdoc.who.int/. 2009. Accessed 28 Nov 2011.
  11. Ministry of Health Malaysia. Management of dengue fever in children. Ministry of Health Malaysia Web Site. http://www.acadmed.org.my/. 2004. Accessed 19 Dec 2007.
  12. Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (NCZVED), Centers for Disease Control and Prevention. Dengue: clinical and public health aspects, (a slide set for health professionals). Centers for Disease Control and Prevention. http://www.cdc.gov/. Feb 2008.
  13. Tomashek KM, Sharp TM, Margolis HS. Dengue. In: Centers for Disease Control and Prevention. Yellow book 2016; 2015. https://wwwnc.cdc.gov/. Accessed 10 Aug 2015.
  14. Philippine Pediatric Society. Revised guidelines on fluid management of dengue fever and dengue hemorrhagic fever 2012. Philippine Pediatric Society Web Site. http://pps.org.ph/. 2012. Accessed 10 Aug 2015.
  15. World Health Organization and Special Programme for Research and Training in Tropical Diseases. Dengue therapy. In: World Health Organization and Special Programme for Research and Training in Tropical Diseases. Handbook for clinical management of dengue. Geneva, Switzerland: WHO Press; 2012 Nov. Accessed 10 Aug 2015.
  16. Capeding MR, Tran NH, Hadinegoro SR, et al; CYD14 Study Group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014 Oct;384(9951):1358-1365. doi: 10.1016/S0140-6736(14)61060-6. PMID: 25018116
  17. World Health Organization. Dengue vaccine research. WHO Web Site. http://www.who.int/. Dec 2015. Accessed 24 Feb 2016.
  18. World Health Organization. Dengue and severe dengue. WHO. http://www.who.int. Apr 2017.
  19. World Health Organization. Dengue vaccine: WHO position paper, July 2016 - recommendations. Vaccine. 2017 Mar;35(9):1200-1201. doi: 10.1016/j.vaccine.2016.10.070. PMID: 28185744
  20. Philippine Pediatric Society, Pediatric Infectious Disease Society of the Philippines. 2017 PPS-PIDSP Clinical practice guidelines on dengue in children. Philippine Pediatric Society. https://pps.org.ph/. Jul 2017. Accessed 04 Sep 2017.
  21. Pediatric Infectious Disease Society of the Philippines. Response from the Pediatric Infectious Disease Society of the Philippines regarding current issues on the use of the dengue vaccine. Pediatric Infectious Disease Society of the Philippines. http://www.pidsphil.org. 12 Dec 2017.
  22. WHO secretariat. Updated questions and answers related to the dengue vaccine Dengvaxia and its use. World Health Organization. http://www.who.int/immunization/diseases/dengue. 22 Dec 2017.
  23. Mustafa MS, Rasotgi V, Jain S, et al. Discovery of fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue control. Med J Armed Forces India. 2015 Jan;71(1):67-70. doi: 10.1016/j.mjafi.2014.09.011. PMID: 25609867
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Natalia Reoutova, 07 Jan 2020

A prospective cohort study of mothers taking antiepileptic drugs (AEDs) and their breastfed infants has found substantially lower AED concentrations in infant vs maternal blood, with nearly half of all obtained AED concentrations in nursing infants being less than the lower limit of quantification (LLoQ).

5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.